Biotech executives building their company pipelines inevitably face the question of whether to diversify their development programs to address more than one therapeutic area. What does success look like if a company is no longer focused or "a cancer company," but instead tackles a variety of perhaps disparate therapeutic areas that lack R&D or market synergies? At this critical decision-making juncture, a wide variety of issues must be addressed. This session will present viewpoints from the R&D and commercial perspectives and address several questions related to this oft-experienced conundrum.

• Share the experiences of executives who have pursued single or multiple therapeutic areas
• Debate how pipeline diversity is perceived by investors and the pharmaceutical industry
• Explore the range of questions executives must ask themselves before they expand their pipelines into dissimilar therapeutic areas